| Edit |   |
|---|
| Antigenic Specificity | NCR1 |
|---|
| Clone | polyclonal |
|---|
| Host Species | Rabbit |
|---|
| Reactive Species | human, mouse, rat |
|---|
| Isotype | n/a |
|---|
| Format | Protein A purified |
|---|
| Size | 100ul |
|---|
| Concentration | 1ug/ul |
|---|
| Applications | WB, IHC-P, IF(IHC-P) |
|---|
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
|---|
| Description | NCR1 Polyclonal Antibody. ? Target Background: Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis. |
|---|
| Immunogen | KLH conjugated synthetic peptide derived from human CD335. Immunogen Range: 170-220/304 |
|---|
| Other Names | LY94; CD335; NKP46; NK-p46; Natural cytotoxicity triggering receptor 1; Lymphocyte antigen 94 homolog; NK cell-activating receptor; Natural killer cell p46-related protein; hNKp46; NCR1 |
|---|
| Gene, Accession # | Gene ID: 9437, SwissProt: O76036 |
|---|
| Catalog # | bs-10027R |
|---|
| Price | |
|---|
| Order / More Info | NCR1 Antibody from BIOSS ANTIBODIES |
|---|
| Product Specific References | Vindevogel, E., et al. (2016) Anticancer Res.36.11:5781-5792. PubMed: 27793900 // Jaime-Ramirez, Alena C., et al. (2017) Mol Ther Oncolytics. // Pan, Pan, et al. (2017) Front Immunol. // Jaime-Ramirez et al. (2017) Mol.Ther.Oncolytics. 5:87-96. PubMed: 28812060 // Pan et al. (2017) Front.Immunol. 8:997. PubMed: 28861089 |
|---|